NEW YORK (GenomeWeb) – Abbott said Wednesday that its first quarter Diagnostics business revenues grew about 2 percent year over year, driven by long-term double-digit growth in its Alinity molecular diagnostic platform and other products.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.